Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.
When 49ers inside linebacker Chris Borland announced his early retirement from the NFL after just one season, the league and fans reacted with shock. But as a father, a neuroscientist and a geriatrician, I can imagine all too well the immense relief that Borland's parents likely felt knowing they would no longer have to watch their son take a beating on Sunday afternoons.
Each year, more than two million Americans suffer from a traumatic brain injury. These injuries can have an enormous impact on an individual’s lifelong health and wellbeing, and may actually raise a person’s risk of developing Alzheimer’s or another dementia later in life. As part of Brain Injury Awareness Month, we’re shining a spotlight on our work to advance research investigating the link between Alzheimer’s disease and traumatic brain injury.
We’ve all heard that diet and exercise are the keys to living healthy lives – but did you know that they may also help to prevent the onset of Alzheimer’s? Or that researchers are investigating drugs that may actually restore memory function? Dr. Roberta Diaz Brinton, a leading researcher funded by the Alzheimer’s Drug Discovery Foundation (ADDF), joined our Founding Executive Director and Chief Science Officer Dr. Howard Fillit to discuss the latest in Alzheimer’s research and drug development for a recent Alzheimer’s Talk hosted by USAgainstAlzheimer’s.
Loss is a natural part of any Alzheimer's patient. The worst may be the loss of language; one of the those human tasks that most of us use without thinking. When words begin to disappear, the brain must draw upon any and all possible reserves. Even when most of the moisture has evaporated, there is still a small pond left. Love. Let us not forget that although they are no longer the people we remember, we should love them just the same. And despite few visible, audible, or behavioral signs from them, they love us right back. These brave men and women have lost many things in their lives. Love isn't one of them.
Did you know that there are currently no FDA-approved treatments for amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer’s disease? It’s a condition that impacts between 10 and 20 percent of all individuals 65 and older, representing an enormous unmet clinical need.
What does it take to translate basic science into drugs for neurodegenerative diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s? We’ll share the answers at our 9th Annual Drug Discovery for Neurodegeneration Conference from March 1-3, 2015 in San Diego, CA.
What does success mean for the Alzheimer’s Drug Discovery Foundation? It means advancing drug discovery for Alzheimer’s disease, supporting the best and brightest scientists in the world and ensuring that individuals have the information they need to ensure a life of cognitive vitality.By any of these measures, it’s safe to say that 2014 was our most transformative year yet.
The wire has been buzzing with news that the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society UK have teamed up to explore the possibility that a commonly prescribed drug for impotence may benefit patients with dementia. This is the first-ever study researching the use of an erectile dysfunction drug for vascular dementia, a form of dementia that affects an estimated one million Americans and is often seen in combination with Alzheimer’s disease.
Family tension. Long-distance travel. Expensive gifts. Extensive preparations. It’s no secret that the holidays can be a stressful time. For families living with Alzheimer’s, that anxiety is often magnified by the trials brought on by an uptick in activities, exposure to unfamiliar places and breaks in routine. We’ve put together a few tips to help you and your loved ones enjoy the holiday season while managing the challenges and changes that come with Alzheimer’s disease.
Recently, the The New York Times covered the news that the Cystic Fibrosis Foundation (CFF) had received a record-breaking $3.3 billion return on its $150 million investment. Even more impressive: the CFF’s early and continuous investment led to the development of the first FDA-approved drug to treat the root causes of cystic fibrosis, rather than the lung disease’s symptoms.